A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

Inclusion Criteria: * Total testosterone level \<300 nanogram per deciliter (ng/dL) \[10.4 nanomole per Liter (nmol/L)\] at each of 2 screening visits * At least 1 symptom of testosterone deficiency, which must include decreased energy or decreased sexual drive * Prostate Specific Antigen (PSA) \<4 nanogram per milliliter (ng/ml) at screening Exclusion Criteria: * Sexual partner who is or becomes pregnant at any time during the study * Use of long-acting intramuscular (IM) testosterone undecanoate or testosterone pellets in the 6-month period prior to screening * Body Mass Index (BMI) \>37 kilogram per square meter (kg/m\^2) at screening * Severe lower urinary tract symptoms and/or significant prostate enlargement * Prolactin lab test result of \>30 ng/mL at screening * Hemoglobin A1c (HbA1c) \>11% at screening * Hematocrit ≥50% (\>54% at elevated altitude) at screening * Current use of any medications, herbal, and/or nutritional supplements that can interfere with testosterone * Dermatologic condition in underarm area that might interfere with testosterone absorption (for example, eczema) or be exacerbated by topical testosterone replacement therapy * Currently receiving treatment with cancer chemotherapy or antiandrogens * Chronic use of systemic glucocorticoids (use for \>14 days within the 3 months prior to screening); use of non-testosterone anabolic steroids within 12 months prior to screening * Competitive athletes involved in a sport in which they may be screened for anabolic steroids * History of use of estrogenizing agents within 12 months prior to screening * History of luteinizing hormone-releasing hormone antagonist or agonist treatment in the last 6 months prior to screening * History of clomiphene or other anti-estrogen treatment in the 3 months prior to screening * Use of finasteride within 3 months prior to screening, or use of dutasteride within 6 months prior to screening * Current use of warfarin or phenprocoumon * History of frequent opioid use: \>1 time/week during any week within 30 days prior to screening * Current use of dopamine receptor agonists (cabergoline, pergolide, bromocriptine) * Have a history of significant central nervous system injuries or disease (including stroke, spinal cord injury, or multiple sclerosis) within 6 months prior to screening * Systolic blood pressure \>170 or \<90 millimeter of mercury (mm Hg) or diastolic blood pressure \>100 or \<50 mm Hg at screening or a history of malignant hypertension * History of unstable angina as defined by Braunwald Classification of Unstable Angina or angina occurring during sexual intercourse in the last 6 months * History of any of the following coronary conditions within 90 days of screening: myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention (angioplasty or stent placement) * Have any supraventricular arrhythmia with an uncontrolled ventricular response \[mean heart rate \>100 beats per minute (bpm)\] at rest, or have any history of spontaneous or induced sustained ventricular tachycardia (heart rate \>100 bpm for ≥30 seconds), or use of an automatic internal cardioverter-defibrillator * Have a history of sudden cardiac arrest * Exhibit any evidence of congestive heart failure \[New York Heart Association (NYHA) Class 2 or above\], within 6 months prior to screening * Have had a new, significant cardiac conduction defect within 90 days prior to screening * Clinical suspicion (or history) of prostate cancer during digital rectal examination at screening * Known or suspected breast cancer (or history of breast cancer) or other active cancer (with the exception of nonmelanotic skin cancer) * Exhibit evidence of severe renal impairment \[creatinine clearance \<30 milliliter per minute (mL/min) as determined by the Cockcroft-Gault formula\] at screening * Exhibit a history of severe liver disease or clinical evidence of hepatic impairment at screening * Have a history of human immunodeficiency virus (HIV) infection * Severe sleep apnea * Untreated hypothyroidism, hypercortisolism or other significant endocrinopathy (other than hypogonadism) that contributes to symptoms of low energy or fatigue